• Home
  • About
  • Links

Feeds:
Posts
Comments
« A year and a half after the economy crashes, and this is what we get?
Pressure on Obama to deliver campaign promises for new trade model »

FDA – cautious on food safety, reckless with prescription drug safety

March 15, 2010 by Sidney Wolfe, M.D.

The new guard at the Food and Drug Administration (FDA) has brought welcome, increased focus and action to protect people from unsafe or possibly unsafe foods. The most recent example is the massive recall recently of products containing hydrolyzed vegetable protein in which the FDA stated that although “no illnesses are known to be associated with this problem of [bacterial] contamination,” the agency was “taking steps to protect the public.”

Three cheers for that. New FDA Commissioner Peggy Hamburg and Principal Deputy Commissioner Joshua Sharfstein are rightly giving muscle to an agency that for too long has let industry call the shots.

However, in contrast to becoming more active in enhancing food safety by removing potentially dangerous products before they have caused harm, though, several FDA decisions in the past year regarding prescription drugs can only be described as reckless.

By deciding not to ban three drugs in particular, the FDA has endangered the lives and health of hundreds of thousands of people. For each of these drugs, there is unequivocal evidence that their dangers, including hundreds of deaths, outweigh their health benefits.

This evidence is so clear that two of the drugs – the pain killer propoxyphene (Darvocet) and the diet drug sibutramine (Meridia) – have been removed or are in the process of being removed from the market in the U.K. and in Europe. The American and European Diabetes Associations recommended a year ago that the third drug, the diabetes drug Avandia, should not be used. In 2009, there were a total of approximately 23 million prescriptions filled for these three drugs in the U.S.

In deciding to ban propoxyphene in mid-2009, the European Medicines Agency (EMA) stated that “the available evidence suggests that the combination of propoxyphene and acetaminophen [as in Tylenol] is no more effective than acetaminophen on its own” and that “the benefits of all medicines containing propoxyphene, either on its own or in combination, do not outweigh their risks.”

An earlier announcement of the eventual ban in the U.K. has resulted in “a major reduction in deaths involving coproxamol [propoxyphene and acetaminophen] compared with the expected number of deaths (an estimated 295 fewer suicides and 349 fewer deaths including accidental poisonings), but no statistical evidence for an increase in deaths involving either other analgesics or other drugs.”

In announcing the UK withdrawal, the government stated: “It has not been possible to identify any patient group in whom the risk-benefit [ratio] may be positive.”

Last year, the FDA ignored the recommendation of one of its own advisory committees to ban propoxyphene, deciding instead to merely increase the warnings. Former FDA Commissioner Dr. Donald Kennedy and former Bureau of Drugs Director Dr. Richard Crout, both at the FDA when it rejected our earlier petition to ban propoxyphene in 1978, now support our petition to ban this drug.

When they recommended the ban of Meridia in January, the EMA stated that its benefits don’t outweigh its risks, based on a 10,000-person study showing significantly increased heart attacks, strokes or cardiovascular deaths in people taking the drug compared with those who took a placebo. The FDA, in contrast, said that it had not yet analyzed the data from this study but will strengthen warning label and have an advisory committee meeting in the fall.

A Canadian study last year found that for every million people using Avandia, instead of a similar but safer diabetes drug, Actos, there would be an excess of 8,300 cases of heart failure and 3,500 excess deaths. These needless cardiac deaths were the reason that the American and European Diabetes Associations concluded that “given that other [treatment] options are now recommended, the consensus group members unanimously advised against using rosiglitazone [Avandia].”

Why the stark difference between the approach to food safety and drug safety?

Doctors Hamburg and Sharfstein have clearly made a decision to take the lead and insist that the agency does a much better job to protect consumers from dangerous food.

Unfortunately, they have deferred to the existing, dangerously flawed leadership in FDA’s Center for Drug Evaluation and Research, on drug safety. They apparently are unwilling to challenge the decisions to leave these three dangerous drugs on the market.

If the agency is to act on the statements Hamburg and Sharfstein made in an editorial in June 2009, that the “overriding purpose [of the FDA is] protecting the public health” and that “[s]ome benefits are not worth the risk,” they will insist on the ban of these three drugs and the replacement of the current top drug officials with those more intent on protecting the public health.

Dr. Sidney M. Wolfe is the director of Public Citizen’s Health Research Group.

Advertisements

Share this:

  • Email
  • Facebook
  • Twitter
  • Reddit

Like this:

Like Loading...

Related

Posted in Consumer Protection, Health, Pharmaceuticals, Product Safety | Tagged FDA, food safety, pharma |

  • Follow Our Tweets!

    • Since his run for office in 2015, Donald Trump’s campaign has spent $13.4 million at Trump’s U.S. businesses. Bef… twitter.com/i/web/status/9… 2 hours ago
    • RT @democracy4ppl: Tonight, @SenWhitehouse @SenWarren @SenMarkey @SenCortezMasto @RonWyden and @SenatorTomUdall are kicking off a series of… 2 hours ago
    • RT @fightfortheftr: IMPORTANT: #NetNeutrality is NOT dead as of today. The repeal hasn’t even gone into effect yet (journalists, please cor… 4 hours ago
  • Support Our Work

  • Socialize With Us

  • Categories

  • Visit Our Other Sites

    • Public Citizen Read our reports and publications
    • Eyes on Trade Challenging globalization
    • Citizen Energy Fighting for a sustainable future
    • Law & Policy Justice for consumers
    • Texas Vox Activism from the Lone Star state
    • Worst Pills An independent pharma watchdog
  • Recent Comments

    Wellescent Health Bo… on The Midmorning Refill: Nancy P…
    Democracy Now! discu… on When it comes to cheating the…
    Marcia Everett on The Midmorning Refill: Mother…
    David Peterson on When it comes to cheating the…
    otto mandarin on Weissman: It’s not a pre…
  • Flickr Photos

    Public Citizen and supporters protest Vice President Mike Pence outside his "Tax Prom" on November 16, 2017Public Citizen President Robert Weissman protests Vice President Mike Pence outside his "Tax Prom" on November 16, 2017The Corruption Cleanup mascot joins Public Citizen to protest Vice President Mike Pence outside his "Tax Prom" on November 16, 2017
    More Photos
  • access to justice Activism arbitration Avandia bailout banking big oil big pharma BP campaign contributions Campaign Finance campaign finance reform Chamber of Commerce Citizens United Citizens United v. FEC Climate Change Congress Consumer Protection corporate power credit cards DISCLOSE Act Don't Get Rolled economics economy elections Energy energy & climate EPA Ethics fair trade FDA fec financial reform first amendment free trade global warming gop government reform gulf of mexico Halliburton Health health & safety health care health care delivery health care reform Jon Stewart Lobbying lobbying and government ethics lobbyists McCain-Feingold medical malpractice money in politics nafta obama offshore drilling oil oilspill oil spill Open Government petition pharma political ads political advertising political contributions politics Rally to Restore Sanity scotus single-payer stephen colbert Supreme Court Transparency Transportation U.S. Chamber of Commerce wall street wto
  • Archives

  • Meta

    • Register
    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.com
  • NetworkedBlogs
    Blog:
    Public Citizen - Citizen Vox
    Topics:
    progressive, reform, politics
     
    Follow my blog
  • Advertisements

Create a free website or blog at WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: